Correction: Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

In the original version of this article (1), the baseline patient characteristic “Not examined” in the Table 1 section “HER2 expression (IHC): central laboratory assessment” was incorrectly labeled and did not report the numbers of patients with non–small cell lung cancer (NSCLC) and other cancers, as well as the total number of patients, exhibiting this particular characteristic. We have corrected these errors by (i) replacing “Not examined” with “Not examined/missing” in the section of Table 1 titled “HER2 expression (IHC): central laboratory assessment” and the subsection of the Results section titled “Demographics and Baseline Characteristics,” and (ii) reporting the number of patients with NSCLC and other cancers and total number of patients with cancers that were identified as “Not examined/missing” in the section of Table 1 titled “HER2 expression (IHC): central laboratory assessment” in the latest online HTML and PDF versions of the article. The authors regret the error.